FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Pernock David					2. Issuer Name and Ticker or Trading Symbol EAGLE PHARMACEUTICALS, INC. [EGRX]							(Ch	eck all applic	cable) r	Person(s) to Iss 10% O	wner
(Last)	(Fi	irst)	(Middle)										Officer below)	(give title	Other (below)	specify
EAGLE PHARMACEUTICALS, INC. 50 TICE BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 04/08/2015											
(Street) WOODC LAKES	CLIFF N.	J	07677	4.	Line) X Form f							Joint/Group Filing (Check Applicable iled by One Reporting Person iled by More than One Reporting				
(City)	(S	tate)	(Zip)													
		Tab	le I - Non-Dei	rivativ	e Se	curities	s Ac	quired, D	ispos	ed o	f, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (Ins	ion Dis		ties Acquire I Of (D) (Ins (A) or (D)	tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported Transact (Instr. 3 a	s Fo Ally (D Collowing (I) I ion(s)	Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$46.81	04/08/2015		A		10,000		(1)	04/07/	/2025	Common Stock	10,000	\$0.00	10,000	D	

Explanation of Responses:

1. The option vests annually over three years, subject to the reporting person's continuous service with the issuer as of the vesting date.

Remarks:

Scott Tarriff, Attorney-in-Fact 04/10/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.